Iranian Pharmaceuticals Industry Analysis Report Summary to the efficiency of the domestic companies This report provides a brief overview on by investigating the structure of productions macro pharmaceutical Industry in Iran. It and compare these productions in the existing identifies and gives a broad introduction to consumer market. In this regard the optimal the investment opportunities in this sector. As production structure and effective control well as assessing the actual and potential over the market sales, as well as high quality advantages and challenges of the industry, productions and productions in the saturated this report includes a briefing on global market has been reviewed to observe the market, followed by the strengths and appropriate investment options in this sector. weaknesses of the industry in regional terms. It has also been tried to get an in-depth insight 1 2018. Key factors affecting the Global pharmaceutical industry pharmaceutical industry in the world on both the supply and demand sides can The pharmaceutical industry is one of be divided into the following categories: the most profitable industries in the world. The stable upward trend along with low a. Population (including population and fluctuations are the distinctive features of this age distribution of the population) sector. Increase in population growth with According to the World Health Organization fundamental and sensitive individual’s need (WHO) world’s population is expected to to health care, has led the industry to increase by one billion people over the next undertake a growing trend. The 10 years and respectively there will be 500 pharmaceutical sector has been less and later million people increase to the population of exposed to economic fluctuations and it has aged over 50 years. been less affected by the economic cycle of boom and recession in comparison to other industries. At present, the volume of pharmaceutical b. GDP per capita industry in the world is almost over one General increase in income and living trillion US dollars, although this amount will standards has always been associated with have been exceeded to 1600 billion dollars by health cost. Income increase, change in the world’s c. Health insurance development and population by age, increase in health status of increase in government health population and changes in life style behavior expenditure of the public, has led us to face a variety of Increase in living standards is always more different illnesses than in the past. For associated with governmental public health example, infectious diseases have been concern, increase in government spending, reduced while chronic diseases and special and the growth in health insurance. disease (cancer, diabetes, neurological, and d. Research and Development: cardiovascular) are increasing, however, High level of cost in research phase is as a their treatment regime is long, complicated key factor affecting pharmaceutical and expensive. industry’s supply side. Patent protection 2 allows a manufacturing company to recoup figure expected to rise to US$400 billion the cost of developing of a particular drug and within three years. The 30% global R&D to enjoy a period of exclusive right to market, funding share in respect to the whole Industry an innovator drug called “brand name”. After reflects its impact on Pharmaceutical expiring a patent on a drug any manufacturing. pharmaceutical company can manufacture The figure blow illustrates the geographic and sell the drug that defines as “generic”. distribution of generic and brand drugs The global annual spending on research and consumption: development is worth US$300 billion, a IMS Outlook for the Global approval of new invented drugs and increase Pharmaceutical Industry: in the number of patients. Consumer spending on diabetes medications Spending levels will be driven by branded in developed and developing countries will drugs primarily in developed markets, along experience an increase of 10%. with the greater use of generics in pharma New hepatitis drug sales growth will be the emerging markets-offset by the impact of next focus by reducing the period of patent expires. treatment, definitive treatment and side the uptick in the number of approvals of the effects new molecular entities (NMEs), leading to a Focus on therapeutic areas related to cancer, new wave of innovation and invention in the diabetes and hepatitis will be important for industry companies’ growth at the global level. Sales of drugs related to the cancer will have the most growth with consideration to 3 The industry sales will experience slower fields like pharmaceutical growth until 2018 after the increasing trend biotechnology in 2014 and 2015, - Pharmaceutical spending is close to Major growth is related to reduction of 20% of total treatment costs expired brand drugs in this period, the - 10 largest companies hold close to production of new medicines and price 50% market share and 10 importing increases. The growth rate is projected to be drugs companies hold more than 73% between 4 to 7 percent. of the importing drug market. Iranian Pharmaceuticals Industry - In terms of value, Antibiotics consumption is nearly a quarter of all Key facts: drug consumption in Iran - Iran is a large pharmaceutical market - Nearly a third of market sales is in the region and has undergone great linked to sales of brand medicines. growth in comparison with - 15 percent increase in the developing countries and the pharma pharmaceutical industry's sales is emerging group, and the market is predicted by the World Health expanding quickly while a major Organization (WHO). share goes to biotechnology drugs, which implies the need to commercialization activities in novel In the following table, market share of Cancer %8 medicines in Iran, according to their therapeutic areas are specified. Endocrinology %5.8 Hematology %5.2 Therapeutic group Shares in drug consumption Respiratory %4 Infection %17 Dermatology %2.6 CNS %10 Gynecology %2.1 Cardiovascular %8.3 4 Population Population growth is an important variable Iran demographic trend for the period 1990- which affects the drug consumption and 2014 is presented in the following diagram. consequently profitability of pharmaceutical industry. 90000000 80000000 70000000 60000000 50000000 40000000 30000000 20000000 10000000 0 up 65 population Population Growth and Aging are “cost if the use and cost of drugs increase with age drivers,” that influences spending on for the average individual within the prescription drugs, Population growth is the population. According to the statistics, in the effect of changes in the size of the population last 4 years, Iran population growth rate has on total drug spending. Other things being been stable at around 1.3%, which shows an equal, an increase in population size will slightly growth compared to previous years. increase total spending. Population aging is Based on population policies, it is predictable the effect of changes in the age distribution of that population growth stays constant or the population on spending. An aging increase slightly in near future. population will result in increased spending . 5 Age groups and medical expenses: 8 7 6 5 4 3 2 1 0 0-1 1-5 5-20 20-40 40-60 up 60 Above figure shows the relative differences in health care costs by age groups. Age composition of the population according to 2010 Census is presented in the following graph: 10000000 9000000 8000000 7000000 6000000 5000000 4000000 3000000 2000000 1000000 0 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 up 80 As shows the above figure, the highest share of the population is accounted for by those aged 25–29. currently by aging of this group, there has been an increase in the median age of the Iran’s population which still have the highest share of the population .Considering the different segment of population, healthcare costs and that the large portion of total population is young the level of health care costs and medication consumption is minimum. Therefor by the aging of the population, spending on health and social care in medium to long term will increase inexorably in Iran. Indicators of health costs in Iran is provided in the following table: 6 Health expenditure (% of Health Health GDP) expenditure, expenditure total public (% of per capita Series Name population, total private public government (current expenditure) US$) 3.70 1.94 1.75 7.45 85 61,306,632 1995 4.09 2.10 1.98 8.46 109 62,426,086 1996 4.51 2.32 2.19 9.72 133 63,616,065 1997 4.59 2.65 1.95 9.16 176 6,780,362 1998 4.60 2.68 1.91 10.61 229 65,850,062 1999 5.09 2.87 2.22 11.88 291 66,812,736 2000 5.12 2.87 2.25 10.09 101 67,696,677 2001 4.74 2.57 2.17 9.81 96 68,522,074 2002 4.72 2.67 2.05 10.12 116 69,321,953 2003 5.33 2.97 2.36 9.58 155 70,122,115 2004 5.07 2.72 2.35 9.26 173 70,923,164 2005 5.11 2.83 2.28 10.53 219 71,720,859 2006 6.35 3.87 2.49 10.07 311 72,530,693 2007 7.20 4.19 3.01 13.31 355 73,370,982 2008 7.28 4.44 2.84 13.43 413 74,253,373 2009 6.26 3.56 2.70 13.87 479 75,184,322 2010 6.64 3.96 2.68 17.53 485 76,156,975 2011 6.69 3.96 2.73 17.53 432 77,152,445 2012 .